Mirum Pharmaceuticals (MIRM) EBITDA (2019 - 2026)

Mirum Pharmaceuticals has reported EBITDA for 8 years, with the latest figure at -$789.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 5099.66% year-over-year to -$789.5 million; the trailing twelve-month figure through Mar 2026 stood at -$796.4 million (down 943.51% YoY), and the FY2025 full-year result was -$22.1 million, up 74.73% from the prior year.
• EBITDA for Q1 2026 stood at -$789.5 million, down from -$4.6 million in the prior quarter.
• The five-year high for EBITDA was $2.6 million in Q3 2025, with the low at -$789.5 million in Q1 2026.
• Average EBITDA over 5 years is -$67.0 million, with a median of -$25.1 million recorded in 2023.
• Year-over-year, EBITDA surged 120.52% in 2025 and slumped 5099.66% in 2026.
• Tracing MIRM's EBITDA over 5 years: stood at -$34.2 million in 2022, then rose by 4.61% to -$32.6 million in 2023, then climbed by 25.67% to -$24.2 million in 2024, then jumped by 81.15% to -$4.6 million in 2025, then tumbled by 17186.29% to -$789.5 million in 2026.
• The last three EBITDA figures came in at -$789.5 million (Q1 2026), -$4.6 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.

Peer Comparison